Refined CLARITY-Based Tissue Clearing for Three-Dimensional Fibroblast Organization in Healthy and Injured Mouse Hearts

Summary

A refined method of tissue clearing was developed and applied to the adult mouse heart. This method was designed to clear dense, autofluorescent cardiac tissue, while maintaining labeled fibroblast fluorescence attributed to a genetic reporter strategy.

Abstract

Cardiovascular disease is the most prevalent cause of mortality worldwide and is often marked by heightened cardiac fibrosis that can lead to increased ventricular stiffness with altered cardiac function. This increase in cardiac ventricular fibrosis is due to activation of resident fibroblasts, although how these cells operate within the 3-dimensional (3-D) heart, at baseline or after activation, is not well understood. To examine how fibroblasts contribute to heart disease and their dynamics in the 3-D heart, a refined CLARITY-based tissue clearing and imaging method was developed that shows fluorescently labeled cardiac fibroblasts within the entire mouse heart. Tissue resident fibroblasts were genetically labeled using Rosa26-loxP-eGFP florescent reporter mice crossed with the cardiac fibroblast expressing Tcf21-MerCreMer knock-in line. This technique was used to observe fibroblast localization dynamics throughout the entire adult left ventricle in healthy mice and in fibrotic mouse models of heart disease. Interestingly, in one injury model, unique patterns of cardiac fibroblasts were observed in the injured mouse heart that followed bands of wrapped fibers in the contractile direction. In ischemic injury models, fibroblast death occurred, followed by repopulation from the infarct border zone. Collectively, this refined cardiac tissue clarifying technique and digitized imaging system allows for 3-D visualization of cardiac fibroblasts in the heart without the limitations of antibody penetration failure or previous issues surrounding lost fluorescence due to tissue processing.

Introduction

Although cardiomyocytes comprise the greatest volume fraction in the heart, cardiac fibroblasts are more plentiful and are critically involved in regulating the baseline structural and reparative features of this organ. Cardiac fibroblasts are highly mobile, mechanically responsive, and phenotypically ranging depending on the extent of their activation. Cardiac fibroblasts are necessary to maintain normal levels of extracellular matrix (ECM), and too little or too much ECM production by these cells can lead to disease^1,2,3. Given their importance in disease, cardiac fibroblasts have become an increasingly important topic of investigation towards identifying novel treatment strategies, especially in attempting to limit excessive fibrosis^4,5,6,7. Upon injury, fibroblasts activate and differentiate into a more synthetic cell type known as a myofibroblast, which can be proliferative and secrete abundant ECM, as well as have contractile activity that helps remodel the ventricles.

While cardiac fibroblasts have been extensively evaluated for their properties in 2-D cultures^6,8,9,10, much less is understood of their properties and dynamics in the 3-D living heart, either at baseline or with disease stimulation. Here, a refined method has been described to tissue clear the adult mouse heart while maintaining the fluorescence of fibroblasts labeled with a Rosa26-loxP-eGFP x Tcf21-MerCreMer genetic reporter system. Within the heart, Tcf21 is a relatively specific marker of quiescent fibroblasts⁴. After tamoxifen is given to activate the inducible MerCreMer protein, essentially all quiescent fibroblasts will permanently express enhanced green fluorescent protein (eGFP) from the Rosa26 locus, which allows for their tracking in vivo.

Numerous well-established tissue clearing protocols exist, some of which have been applied to the heart^{11,12,13,14,15,16,17}. However, many of the reagents used in different tissue clearing protocols have been found to quench endogenous fluorescence signals¹⁸. Additionally, the adult heart is difficult to clear due to abundant heme group-containing proteins that generate autofluorescence¹⁹. Therefore, the goal of this protocol was to preserve fibroblast marker fluorescence with the simultaneous inhibition of heme autofluorescence in the injured adult heart for optimal 3-D visualization in vivo^{12,13,14,16,17,20}.

Previous studies attempting to examine the cardiac fibroblast in vivo employed perfused antibodies to label these cells, although such studies were limited by antibody penetration and cardiac vascular structure^14,16,17,20. Although Salamon et al. have shown tissue clearing with maintenance of topical neuronal fluorescence in the neonatal heart, and Nehrhoff et al. have shown maintenance of fluorescence marking myeloid cells, maintenance of endogenous fluorescence through the entire ventricular wall has not yet been demonstrated, including the visualization of adult cardiac fibroblasts at baseline or following injury^13,20. This tissue clearing protocol refines a mixture of previous protocols based on the CLARITY method (clear lipid-exchanged acrylamide-hybridized rigid Imaging/immunostaining/in situ-hybridization-compatible tissue hydrogel) and PEGASOS (polyethylene glycol (PEG)-associated solvent system). This refined protocol permitted a more robust examination of cardiac fibroblasts in the mouse heart at baseline and of how they respond to different types of injury. The protocol is straightforward and reproducible and will help characterize the behavior of cardiac fibroblasts in vivo.

Protocol

All experiments involving mice were approved by the Institutional Animal Care and Use Committee (IACUC) at Cincinnati Children’s Hospital Medical Center. The institution is also AAALAC (American Association for Accreditation of Laboratory Animal Care) certified. Mice were euthanized via cervical dislocation, and mice undergoing survival surgical procedures were given pain relief (see below). All methods used for pain management and euthanasia are based on recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. All mice were housed in corn cob bedding units with water and food available at all times. Mice were housed 4 to a cage with the same sex. For surgery or uninjured tissue clearing, equal numbers of 6–8-week-old male and female mice were used.

NOTE: Sterile surgical conditions were maintained in all surgeries. The surgeon changed into clean scrubs and a sterile gown and then donned shoe covers and a hairnet. The surgeon then scrubbed their hands with chlorhexidine and donned sterile surgical gloves. The surgeon was assisted by a technician who sedated, shaved, and scrubbed the incision site 3 times each, alternating between 2% chlorohexidine gluconate and 70% isopropanol. The mice were then brought to the surgeon, and surgery was performed. Between animals, the instruments were sterilized in a bead sterilizer.

1. Cre recombination

1. Cross Rosa26-loxP-eGFP mice (Rosa26-nLacZ [FVB.Cg-Gt(ROSA)26Sortm1 (CAG-lacZ,-EGFP)Glh/J]) with Tcf21-MerCreMer mice (Figure 1A)^6,21.
2. When the offspring of this cross reach 6 weeks of age, administer an intraperitoneal injection of 75 mg/kg of tamoxifen dissolved in corn oil.²² Administer this tamoxifen twice, 48 h apart (Figure 1B).
3. After tamoxifen injections, put the mice on a diet of tamoxifen food (~0.4 g/kg tamoxifen citrate) for one week. After one week of tamoxifen chow, return the mice to a normal autoclaved chow diet for one week before performing surgery (Figure 1B). Designate an appropriate number of mice (3 per surgical condition) to be uninjured controls. Sacrifice these mice, and proceed to the clearing process delineated below following the one week of normal chow diet.
4. Following the tamoxifen regimen and recombination, perform surgery.

2. Surgical models

1. Ischemia/reperfusion (I/R)^23,24
   1. Anesthetize mice with 1.5% isoflurane gas in room air in a ventilated box; shave their chests and necks with electric clippers, and then scrub the shaved areas with a 2% chlorhexidine gluconate-soaked swab.
   2. Use artificial tear ointment to prevent dryness during surgery by placing ointment on the eyes of the sedated mice.
   3. Perform a mid-neck cut using surgical scissors to allow visualization of the trachea. Intubate with a 20 G catheter by placing the intubation tube into the trachea and visualize the tracheal catheter through the mid-neck incision. Place the mice on a ventilator while sedated with isoflurane gas (1.5%) in room air.
   4. Make an incision under the left front limb with surgical scissors, and cut the intercostal muscles between ribs 3 and 4. Spread the ribs open using a retractor.
   5. Place a small sponge soaked in saline between the lung and the heart to prevent damage to the lung.
   6. Using a fishhook needle (6.5 mm, 3/8 c), tie the left coronary artery with a releasable slip knot using 8-0 prolene.
   7. Remove the sponge using forceps.
   8. Suture the intercostal muscles closed using 4-0 braided silk and a continuous suture while also exteriorizing the end of the 8-0 prolene slip knot.
   9. Close the skin incisions using topical tissue adhesive with the end of the occluding slip knot protruding.
   10. After one hour of occlusion, pull the exterior end of the slip knot to internally release the coronary artery occlusion, relieving the ischemia and causing reperfusion.
   11. Administer 0.02 mL of a 1 mg/mL extended release buprenorphine via subdermal injection (72 h release) as a pain reliever, and place the mice in an oxygenated incubation chamber at 37 °C, separate from other animals. Monitor the mice at least every 15 min until they have recovered from anesthesia and are able to maintain a sternal or sitting position. Return the mice to their regular housing.
   12. Assess the animals for pain and distress for 48 h following surgery, and monitor the incision site daily until fully healed.
   13. Observe the mice for hydration, nourishment, and overall well-being following surgery until sacrifice.
2. Myocardial infarction (MI)^25,26,27
   1. Perform steps 2.1.1–2.1.7.
   2. Use a continuous suture to close intercostal muscles using 4-0 braided silk.
   3. Close the skin incision using topical tissue adhesive.
   4. Perform steps 2.1.11–2.1.13.
3. Angiotensin II/phenylephrine micro-osmotic pump infusion
   1. Prepare Prepare a 10 μg/μL working solution of angiotensin II and 500 μg/μL working solution of phenylephrine under sterile conditions (i.e., in a laminar flow hood) by adding 1 mg of angiotensin II to 100 μL of sterile phosphate buffered saline (PBS) and 250 mg of phenylephrine hydrochloride into 500 μL of PBS.
   2. Calculate the dilution of each working solution and final volume to dispense to the micro-osmotic pump based on mouse weight.
      NOTE: For instance, a 20 g mouse requires 20 g x 14 days x 1.5 μg/day = 420 μg angiotensin, or 42 μL of working solution, as well as 20 g x 14 days x 50 μg/day = 14000 μg phenylephrine hydrochloride, or 28 μL of working solution.
   3. For the weight of each mouse, dilute the working stock of the drug in sterile PBS and fill the micro-osmotic pumps (0.25 μL/h, 14 days, approximately 100 μL) using a 27 G needle and 1 mL syringe.
      NOTE: This will generate a flow rate of 1.5 μg∙g^-1∙day^-1 of angiotensin II and 50 μg∙g^-1∙day^-1 of phenylephrine hydrochloride once placed in the mice.
   4. Anesthetize the mice with 1.5% isoflurane inhalation (to effect) in a ventilated chamber containing room air.
   5. Place the anesthetized mice on a sterile surgical table in the opine position, and maintain anesthesia with isoflurane gas inhalation (1.5%) through a nose cone.
   6. Use artificial tear ointment on the animal’s eyes to prevent dryness during surgery.
   7. Shave the fur over the implantation area with electric hair clippers, and sterilize the area to be cut using ethanol and a sterile swab. Make a small incision (approximately 1 cm) with surgical scissors in the epidermal layer of the mouse skin on the right lateral side of the back, below the shoulder blade. Use the dull sides of a pair of surgical scissors to gently stretch the skin in and around the area of implantation to insert the minipump.
   8. Place the micro-osmotic pump within the incision, and physically maneuver it to the left of the dorsal midline of the mouse by manually massaging the pump under the skin.
   9. Close the incision via continuous suture using 4-0 silk with a taper point needle.
   10. Following pump implantation, administer slow release buprenorphine at a dose of 0.1 mg/kg body weight via subdermal injection for analgesia (72-h slow release). Place the mice in an oxygenated incubation chamber at 37 °C, separate from other animals. Monitor the mice at least every 15 min until they recover from anesthesia and can maintain a sternal or sitting position.
   11. Upon recovery from anesthesia in the 37 °C warming chamber, place the mice back in their standard housing units.
   12. Monitor the mice for pain and distress for 48 h following surgery, and monitor the incision site daily until fully healed.
   13. Observe the mice for hydration, nourishment, and overall well-being following surgery until sacrifice.

3. Clearing adult mouse hearts using a modified active CLARITY protocol

1. Prepare a clean surgical area by sterilizing the surgery surface and all surgical tools with 70% ethanol. Prepare a solution of cold 1x PBS and 4% paraformaldehyde (PFA) in PBS (100 mL each). Wear gloves, lab coat, face mask, and eye protection.
2. Prepare heparin buffer by diluting 10 units of heparin in 0.9% w/v sodium chloride solution. Inject each mouse intraperitoneally with 60 μL of heparin-NaCl using a 1 mL syringe and 27 G needle.
3. Five minutes after the injection of heparin-NaCl solution, anesthetize the mice using 1.5% isoflurane inhalation (to effect) in a ventilated chamber containing room air.
4. Euthanize the mice by cervical dislocation, wherein the back of the head is held with the flat, closed end of forceps, while the spinal column is dislocated by pulling the tail.
5. Clean the ventral surface of the mouse with 70% ethanol on a cotton swab. Make a 3 cm transverse incision approximately 3 cm below the xiphoid process using surgical scissors.
6. Separate the skin from the underlying abdominal wall tissue by degloving the abdomen up to the xiphoid process (hold the skin closest to the tail and pull the skin closest to the head up toward the ribcage). Make a 2 cm transverse incision in the subcutaneous abdominal wall tissue 3 cm below the xiphoid process using surgical scissors. Make a vertical cut from this transverse incision, up the midline and through the ribcage. Pin the ribcage back, exposing the heart.
7. Use a 27 G needle and 10 mL syringe to inject cold PBS into the superior vena cava and aorta (any positional manipulation of the heart should be done carefully with blunt forceps to avoid puncture) to clear blood from the heart.
   NOTE: Sufficient perfusion can be noted by tail twitch and discoloration of the lungs.
8. Use a 27 G needle and 10 mL syringe to inject cold 4% PFA into the superior vena cava and aorta to begin the fixation process.
9. Excise the hearts. The atria, right ventricle and septum, and left ventricle should be separated using a straight-blade scalpel. Place this tissue into a 15 mL centrifuge tube filled with cold 4% PFA, and place on a nutator at 4 °C overnight.
10. Wash the heart 3 times for 1 h each with cold 1x PBS to remove excess PFA.
11. Prepare the hydrogel (termed A4P0 for relative acrylamide/polyacrylamide composition) by mixing the following chemicals in a 15 mL centrifuge tube: 10% of 40% acrylamide, 10% 1x PBS, 80% distilled water.
12. Add the 0.25% solution of the photoinitiator (2,2-Azobis[2-(2-imidazolin-2yl)propane)dihydrochloride) to the hydrogel solution just prior to submerging the heart in the hydrogel.
13. Place the heart in a conical tube containing the hydrogel. Wrap the conical tube in foil, and incubate overnight at 4 °C without physical disturbance.
14. After approximately 14 h at 4 °C, move the conical tube containing the heart to a 37 °C bead bath.
15. After 2.5 h in the bead bath, remove the heart from the hydrogel carefully with forceps.
16. Wash the hearts 3 times for 1 h each in a 15 mL conical tube containing 1x PBS at 37 °C on a nutator.
17. Place the hearts in the basket of the active electrophoresis machine using forceps, and place the lid on basket. Ensure that the lid is securely in place.
18. Fill the active electrophoresis chamber reservoir with electrophoretic clearing solution by pouring solution into the chamber.
19. Once the chamber is full of electrophoretic clearing solution, the basket containing the heart can be submerged. Place the cap on the electrophoresis machine securely.
20. Run the electrophoresis machine at 1.5 A, 37 °C for 1.5 h.
21. Following 1.5 h of electrophoresis, check the hearts visually to ensure that no opaque tissue remains. If regions of the tissue are still opaque, re-submerge the heart in electrophoresis solution in the electrophoretic chamber, and continue electrophoresis for 0.5 h at a time.
    NOTE: Electrophoresis should be discontinued at first signs of tissue damage (such as tissue fraying).
22. Wash the hearts in 15 mL conical tube containing 1x PBS for 1 h, 3 times each, at 37 °C on a nutator.
23. Submerge the hearts in a 15 mL conical tube containing N,N,N′,N′-Tetrakis(2-Hydroxypropyl)ethylenediamine—a decolorizing agent that reduces heme autofluorescence.
    NOTE: This solution should be changed every 24 h until the hearts are completely clear (approximately 2 days).
24. Wash the hearts in a 15 mL conical tube with 1x PBS 3 times for 1 h each to remove excess decolorizing agent.
25. Prepare Refractive Index Matching Solution (RIMS) by combining 30 mL of 0.02 M phosphate buffer, 40 g of 5-(N-2, 3-dihydroxypropylacetamido)-2, 4, 6-tri-iodo-N, N'-bis (2, 3 dihydroxypropyl) isophthalamide with stirring (must be completely dissolved—this can take up to an hour), 5 mg of sodium azide, 50 µL of Tween20, and 1 g of 1,4-diazabicyclo[2.2.2]octane, and adjust the pH to 7.5.
26. Equilibrate the hearts in RIMS for 48 h prior to imaging.

4. Imaging cleared hearts using an upright single photon confocal microscope

NOTE: The imaging apparatus consists of the bottom half of a 10 cm glass Petri dish, a 3D printed bottom reservoir, a round glass coverslip, and a 3D printed top reservoir (Figure 1C–E). 3D printed materials were made in-house by the Cincinnati Children’s Hospital Clinical Engineering Department.

1. Use vacuum grease to seal the 3D printed bottom reservoir into a glass Petri dish by putting a thin layer of vacuum grease onto the bottom of the 3D printed piece (Figure 1C).
   NOTE: The reservoir should be the same height as the sample being imaged (i.e., the sample should not be compressed by the glass coverslip placed on top of it, and the sample also should not be able to float and move within the reservoir).
2. Fill the reservoir with RIMS, and remove all bubbles with a pipet tip. Place the heart in the RIMS carefully with the left ventricular wall facing up, ensuring that no bubbles are introduced into the solution.
3. Adhere a glass coverslip to the bottom surface of the 3D printed top reservoir piece (Supplemental Figure 1A) using vacuum grease (again by placing a thin layer of vacuum grease onto the 3D printed piece, and placing it onto the cover slip) (Figure 1D).
4. Place the glass coverslip and top reservoir, coverslip side down, onto the bottom reservoir (Supplemental Figure 1B), without the introduction of bubbles. The adhesion between the RIMS and cover slip will provide a seal between the top and bottom reservoir pieces (Figure 1E).
5. Fill the top reservoir with glycerol for use with a 10x glycerol immersion objective.
6. Use a single photon microscope outfitted with a multiphoton confocal scan head to image the cleared hearts.
7. Lower the stage of the single photon microscope, and place the Petri dish containing the sample in the center of the stage. Raise the stage and lower the 10x glycerol immersion objective into the glycerol in the top reservoir of the sample apparatus. Ensure that the sample is in focus by looking at the edge of the sample using the eyepieces.
8. Switch from eyepiece view to camera view on the computer by clicking on the live button.
   1. Set the X and Y parameters by first locating the widest part of the tissue sample, which should be at the bottom of the Petri dish.
   2. Click on ND Acquisition and custom multipoint. Create multipoints by first finding the middle of the tissue sample by using the joystick to sweep left to right and top to bottom.
   3. Then, based on the size of the tissue, determine the tiling size needed (typically 6 x 5 for a 6–8-week-old mouse heart). Do this by running test imaging by only capturing X and Y parameters (uncheck z under the ND Acquisition tab) to check whether the entire length and width of the tissue were captured.
9. To set z parameters, open the XYZ navigation, and click on the up and down icons until finding the top and bottom of the sample.
   1. Open the Z intensity correction panel and adjust the fluorescence at the top, middle, and bottom of the tissue to correct for tissue density by increasing or decreasing the laser power at each z point. Set these by clicking on the set arrow at the right of the Z Intensity Correction panel.
   2. Set the Z step size in the ND Acquisition panel to 5 μm.
10. After the X, Y, and Z parameters of the heart are delineated and z-intensity correction is set, use the automated upright microscope with a 10x glycerol immersion objective with a resonant scanner and gallium arsenide phosphide photomultiplier tubes (GaAsP PMTs) to image the cleared hearts. Ensure that the XY and Z tabs are checked under ND acquisition, and press Run Z correction.
11. Stitch, unmix, and denoise the resulting images by opening the multipoint image in the processing software and clicking on the stitch button. Under image, click on blind unmixing, 2 channel, and then find. and Under image, click on denoise.ai, then click on the fluorescent channel of choice (i.e., GFP).
    NOTE: This process results in a 3D image of GFP-positive fibroblasts in the entire left ventricle.
12. Use secondary analysis software to further identify patterns and trends in the dispersion of cardiac fibroblasts. Use the Spots function by running the spots wizard program.

Results

Cardiac fibroblasts are essential for baseline function of the heart as well as for response to cardiac injury. Previous attempts to understand the arrangement and morphology of these cells have been conducted largely in 2-D settings. However, a refined cardiac tissue clearing (Figure 2) and 3-D imaging technique has been published, which allows for the advanced, more detailed visualization of cardiac fibroblasts. With this imaging technique, fibroblasts were found to be densely packed and have a spindled morphology in uninjured hearts (Figure 3, Supplemental Videos S1–4).

After left ventricular tissue clearing had been accomplished in an uninjured heart, the protocol was applied to several injury models to examine how this clearing protocol would perform when studying injured heart tissue. Mice were subjected to I/R injury by temporary closure of the left coronary artery (LCA) for 1 h followed by reperfusion lasting 3, 7, 14, or 28 days. These experiments showed that there was a loss of cardiac fibroblasts in the ischemic region right after I/R injury, but that by day 7 and day 14, fibroblasts migrated or proliferated to repopulate this area of the injured heart. By day 28, the cardiac fibroblast population surrounding the injured areas of the heart were at their greatest density (Figure 4, Supplemental Videos S5–8).

MI injury is a surgical model resulting from permanent LCA ligation (no reperfusion). Hearts that had undergone MI surgery were excised at 1.5 and 3 days following surgery for fixation, clearing, and analysis. There were very few fibroblasts remaining in the injured left ventricle at 1.5 days following surgery (Figure 5A, Supplemental Video S9). However, by day 3, fibroblasts expanded and were present in most of the left ventricle except for one small region, presumably having migrated in and/or proliferated from a population in the border zone (Figure 5B, Supplemental Video S10). Again, analysis software was used to better visualize fibroblast localization, and areas of loss of cardiac fibroblasts were outlined in orange (Figure 5). This analysis better showed the initial loss of cells at day 1.5 following MI and how fibroblasts either proliferated or migrated into that damaged area by day 3 to ostensibly repair the area and form a scar.

In addition to ischemic injury, the reaction of cardiac fibroblasts to high blood pressure is not well understood. To discover the response of these cells to high blood pressure, angiotensin II and phenylephrine were administered. Angiotensin II and phenylephrine (Ang/PE) are drugs that cause persistent high blood pressure and cardiac fibroblast activation with areas of interstitial fibrosis, confirmed through application of this tissue clearing protocol to ang/PE treated hearts (Figure 6A)^5,28. In contrast to ischemic surgery, infusion of Ang/PE over several weeks does not result in loss of cardiac tissue and wall thinning. Instead, a different result was observed in fibroblast behavior following this injury.

As the heart pumps, the myocardium twists, following a right-handed helix pattern^29,30,31. In the Ang/PE model of injury, the fibroblasts aligned along the axis of this right-handed helix contraction pattern using the refined tissue clearing protocol (Figure 6B). The hypothesis to explain this behavior is that cardiac fibroblasts were sensing the direction of ventricular wall strain and aligning within the myofibers to provide the greatest support within the ECM as the fibrotic response acutely unfolded during agonist infusion (Figure 7). Another interesting finding was that the fibroblasts appeared small and rounded, as opposed to the spindle shape seen in models of I/R and MI injury (Figure 6, Supplemental Video S11).

Figure 1: Mice and materials used for tissue clearing hearts.
(A) Schematic of breeding strategy for Tcf21-MerCreMer (mcm) x Rosa26eGFP mice used for tissue clearing. (B) Timeline of tamoxifen treatment and surgery performed in mice. Uninjured mice sacrificed on day 14. (C) 3-D printed well to hold heart tissue sealed to a glass Petri dish with vacuum grease. (D) Addition of a round coverslip vacuum grease sealed to the top of the 3-D printed well set on top of the bottom well. (E) Tissue cleared heart in the bottom well of the tissue holding apparatus, filled with Refractive Index Matching Solution (RIMS). Coverslip (as in D) and top 3-D printed well piece laid over the bottom 3-D printed reservoir component, containing cleared heart tissue. Glycerol is added to the top reservoir for glycerol immersion microscopy. Scale bars = 1 cm. Reservoir blueprints can be found in Supplemental Figure 1. Abbreviation: eGFP = enhanced green fluorescent protein. Please click here to view a larger version of this figure.

Figure 2: Visual appearance of cardiac tissue clearing stages.
(A) From left to right: uncleared left ventricle, electrophoresed left ventricle, electrophoresed left ventricle treated with crosslinker, electrophoresed left ventricle treated with crosslinker and incubated in RIMS. (B) Uncleared and cleared whole mouse heart. (C) Left: uninjured, uncleared left ventricle. Right: uninjured, cleared left ventricle. (D) Left: Uncleared MI injured left ventricle. Right: Cleared MI injured left ventricle. Scale bars = 0.5 cm. Abbreviation: MI = myocardial infarction. Please click here to view a larger version of this figure.

Figure 3: Efficacy of novel clearing method for uninjured and sham-operated cleared hearts.
Cleared (A) uninjured (scale bar = 400 μm) and (B) sham-operated hearts (scale bar = 500 μm) with Tcf21mcm x Rosa26eGFP fibroblasts (green) and pseudocolored areas of increased fluorescence (purple) showing fibroblast localization. Accompanying videos showing fibroblast videos can be found in Supplemental Videos S1–2. Still images show background clearing and maintenance of fibroblast-endogenous fluorescence (green). Please click here to view a larger version of this figure.

Figure 4: Attenuation of loss of fibroblasts in ischemia/reperfusion-injured cleared hearts over time.
Cleared cardiac tissue from the indicated I/R time points with Tcf21MerCreMer (mcm) x Rosa26eGFP fibroblasts (green), pseudocolored areas of increased fluorescence (purple) showing fibroblast localization, and orange outlining areas devoid of fibroblasts. Top row: still images of left ventricles from I/R-injured cleared hearts. Bottom row: still images of left ventricles from I/R-injured cleared hearts with Imaris spots function used to see fibroblast patterns more easily in the whole left ventricle. Videos of I/R-injured cleared hearts showing not only gross patterning of fibroblasts, but also clear images of individual fibroblasts and their morphologies can be found in Supplemental Videos S5–8. Scale bars = 500 μm. Abbreviation: I/R = ischemia/reperfusion. Please click here to view a larger version of this figure.

Figure 5: Attenuation of loss of cardiac fibroblasts following injury in myocardial infarction-injured cleared hearts over time.
Cleared cardiac tissue from MI hearts with Tcf21MerCreMer (mcm) x Rosa26eGFP fibroblasts (green), pseudocolored areas of increased fluorescence (purple) showing fibroblast localization, and orange outlining areas devoid of fibroblasts. Top row: Still images of tissue cleared left ventricles from MI-injured hearts (green). Bottom row: still images of tissue cleared left ventricles from MI-injured hearts (green) with Imaris spots function (purple) overlaid to show gross fibroblast distribution. Videos of tissue cleared left ventricles from MI-injured hearts show gross fibroblast arrangement in the heart as well as the positioning and morphology of individual fibroblasts in this 3D in vivo model (Supplemental videos S7–8). Scale bars: 1.5 day = 1000 μm, 3 day = 700 μm. Abbreviation: MI = myocardial infarction. Please click here to view a larger version of this figure.

Figure 6: Cleared tissue from Angiotensin/Phenylephrine-treated hearts.
(A) Schematic showing how Angiotensin/Phenylephrine pumps are used to administer drugs over a two-week period following tamoxifen activation of Tcf21^MCM x eGFP. (B) Still image, still image + Imaris spots, and video showing fibroblast organization and morphology in Ang/PE-treated hearts (Supplemental Video S11) Scale bars = 500 μm. Abbreviations: Ang/PE = angiotensin II/phenylephrine; eGFP = enhanced green fluorescent protein. Please click here to view a larger version of this figure.

Figure 7: Representative images of observed fibroblast pattern in Angiotensin/Phenylephrine-treated hearts.
(A, C, and D): Images of right-handed helix twisting pattern of fibroblasts from the perspective of the outside of the ventricle. (B) Image of fibroblast patterning from the perspective of the inside of the ventricle. Arrows highlight linear groups of fibroblasts that make up the twisting pattern. Scale bars = 500 μm. Please click here to view a larger version of this figure.

Supplemental Figure 1: 2D renderings of imaging reservoir apparatus. (A) 2D rendering of bottom half of imaging reservoir. This reservoir is sealed to the Petri dish with vacuum grease. The heart is placed in the center opening and submerged in RIMS. (B) 2D rendering of top half of imaging reservoir. Glass coverslip is adhered to flat bottom of this piece with vacuum grease. This is gently placed on top of bottom reservoir. Top reservoir can then be filled with glycerol for imaging. Units in mm. Abbreviations: 2D = two-dimensional; RIMS: Refractive Index Matching Solution. Please click here to download this figure.

Video S1: Uninjured tissue cleared heart. Cardiac fibroblasts (green) in an uninjured left ventricle were small, and many were rounded with no more than two cellular projections. Please click here to download this video.

Video S2: Sham tissue cleared heart. Cardiac fibroblasts (green) in the left ventricle of a sham-operated mouse heart were small and mostly round with few projections, similar to what was seen in uninjured hearts. Please click here to download this video.

Video S3: Detailed fibroblast view through the ventricular wall of an uninjured heart. This video begins on the interior ventricular wall and zooms toward the exterior of the heart. Cardiac fibroblasts (green) were shown in detail and were observed to have rounded or slightly elongated cell bodies with no more than two cellular projections. Please click here to download this video.

Video S4: Detailed view of section of left ventricular wall of uninjured heart. This ~300-μm-wide section of the cleared uninjured mouse heart shows the 3-D arrangement of cardiac fibroblasts (green) and their morphologies in detail. Please click here to download this video.

Video S5: Cleared left ventricle of 3 day I/R. Detailed view of the left ventricle showed that following I/R injury, there is an area of cardiac fibroblast loss. It was also apparent that fibroblasts (green) developed a much more elongated shape in this injured condition in comparison to the more rounded morphologies seen in uninjured and sham hearts. Abbreviation: I/R = ischemia/reperfusion. Please click here to download this video.

Video S6: Cleared left ventricle of 7 day I/R. Detailed view of the left ventricle shows that by 7 days following I/R injury, the area lacking in fibroblasts was smaller than that seen by day 3 following I/R injury. There were more fibroblasts (green) present, and interestingly, new cell morphologies were present. Specifically, some fibroblasts had rounded cell bodies with multiple protrusions, potentially indicating a new or developed role of fibroblasts in this environment. Abbreviation: I/R = ischemia/reperfusion. Please click here to download this video.

Video S7: Cleared left ventricle of 14 day I/R. Detailed view of left ventricle showed that there was still an area central to the ventricular wall that had very few fibroblasts but fibroblasts (green) on the periphery of this void maintained the highly elongated morphology seen in day 7 post-I/R samples. Interestingly, the few fibroblasts that were present in the injured region had a morphology like that in uninjured hearts—small and rounded. Abbreviation: I/R = ischemia/reperfusion. Please click here to download this video.

Video S8: Cleared left ventricle of 28 day I/R. Detailed view of cardiac fibroblasts (green) on day 28 following I/R injury showed that there was a small area in the injured region that lacked fibroblasts. It was also observed that there was a region of high fibroblast density surrounding this region, and that the morphologies in this dense area were highly elongated. Abbreviation: I/R = ischemia/reperfusion. Please click here to download this video.

Video S9: Cleared left ventricle of 1.5 day MI. There were very few cardiac fibroblasts (green) remaining in the injured left ventricle at 1.5 days after MI, cardiac fibroblast death throughout this region of the ventricle. Abbreviation: MI = myocardial infarction. Please click here to download this video.

Video S10: Cleared left ventricle of 3 day MI. There was a large area devoid of cardiac fibroblasts 3 days after MI, but some cardiac fibroblasts (green) re-appeared in the ventricle, unlike the results found following 1.5 days of MI. Also, cardiac fibroblast morphology profiles were different than those seen in I/R injured hearts. Here fibroblasts were elongated but there were others that had rounded cell bodies (larger than those seen in uninjured hearts) and a subpopulation of these had many cell projections. Abbreviations: MI = myocardial infarction; I/R = ischemia/reperfusion. Please click here to download this video.

Video S11: Cleared left ventricle of Ang/PE-treated mice. There was no apparent loss of cardiac fibroblasts (green) following Ang/PE treatment. However, cardiac fibroblasts were mostly small and rounded or small and elongated and seemed to align with the contractile patterns of the heart. Abbreviation: Ang/PE = angiotensin II/phenylephrine. Please click here to download this video.

Discussion

This article presents a refined method for tissue clearing that allows for visualization of cardiac fibroblasts in vivo, both at baseline and following injury, to characterize and better understand fibroblasts in the mouse heart. This enhanced protocol addresses limitations in existing tissue clearing protocols that have attempted to identify specific cell types in the adult or neonatal heart^{12,13,14,16,17,20}. In the initial attempts to clear the mouse heart, the passive CLARITY technique was used, wherein the heart was left in a clearing buffer on a nutator for approximately 1 week to allow for passive distribution of the buffer throughout the tissue^15,18. This process only produced clearing of approximately 80 μm of depth into the tissue (data not shown), which is consistent with previous observations whereby several weeks were needed to clear a 1 day-old neonatal mouse heart¹³. Active CLARITY using an active electrophoresis system allowed for deeper clearing through the entire ventricular wall, approximately of 700 μm–1 mm deep, over a shorter time frame^12,18.

However, using this previously published active CLARITY protocol led to a loss of fibroblast fluorescence with high levels of tissue autofluorescence, which had previously been noted to occur in active CLARITY by Kolesova et al.¹². To allow for maintenance of fibroblast fluorescence, the appropriate fixation protocol was found to be of utmost importance. Too short of a fixation process caused loss of fluorescence during electrophoresis. Too long of a fixation process caused loss of fluorescence itself. Therefore, overnight fixation at 4 °C in 4% PFA was found to be optimal. To ameliorate the background fluorescence issue, a decolorization soak (a principle borrowed from the CUBIC method of clearing) was employed to reduce heme binding within myoglobin, and therefore reduce autofluorescence caused by this chromophore¹⁸. Decolorization treatment resulted in more robust clearing of background fluorescence, with maintenance of reporter fluorescence so that the labeled fibroblasts were more pronounced (Figure 2A).

Finally, to allow for full optic transparency, the tissue was equilibrated in Refractive Index Matching Solution (RIMS) (Figure 2B–D). By matching the refractive index of the tissue with its surroundings, this increased the optic transparency of the tissue, allowing for deeper imaging. High speed resonant scanning was then used to image tissue as it is faster than galvanometric scanning. Because mouse hearts are slightly different sizes, individual XY imaging parameters and Z intensity corrections were set. With these parameters, it was possible to image through the uninjured heart to visualize fluorescent fibroblasts in approximately 4 h (Figure 3). Image quality was improved in post-imaging processing by using the unmixing and denoising analysis software to reduce background and clarify the fluorescence present in the image. Additionally, secondary analysis software was used to highlight the localization of fluorescent fibroblasts. This post-imaging analysis was used to clearly annotate cardiac fibroblasts by eliminating background voxel-by-voxel (Figure 3, Figure 4, Figure 5, Figure 6).

This optimized CLARITY protocol has been applied to optically clear both injured and uninjured hearts. This allows for a better understanding of the reaction of cardiac fibroblasts to injury. These injuries included a time course of MI and I/R, as well as Ang/PE dosing. As ischemic injury weakens cardiac tissue, it is critical that greater care is taken during electrophoresis to maintain tissue integrity. Indeed for both I/R and MI injury, a shorter period of electrophoresis (≤1.5 h) is required³². Previous studies have not considered the effects of injury on the tissue clearing process. The newly optimized protocol presented here accommodates for injury, allowing for clearing without further destruction of the tissue.

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
4-0 braided silk	Ethicon	K871H
8-0 prolene	Ethicon	8730H
40% Acrylamide Solution	Bio-Rad	1610140
Angiotensin II	Sigma	A9525-50G
Artificial Tear Ointment	Covetrus	048272
DABCO (1,4-diazabicyclo[2.2. 2]octane)	Millipore Sigma	D27802-25G
GLUture topical tissue adhesive	World Precision Instruments	503763
Heparin	Sigma	H0777
Imaris Start Analysis Software	Oxford Instruments	N/A
Micro-osmotic pumps	Alzet	Model 1002
Nikon Elements Analysis Software	Nikon	N/A
Nikon A1R HD upright microscope	Nikon	N/A
Normal autoclaved chow	Labdiet	5010
Nycodenz, 5- (N-2, 3-dihydroxypropylacetamido)-2, 4, 6-tri-iodo-N, N'-bis (2, 3 dihydroxypropyl) isophthalamide	CosmoBio	AXS-1002424
Paraformaldehyde	Electron Microscopy Sciences	15710
Phenylephrine Hydrochloride	Sigma	P6126-10G
Photoinitiator	Wako Chemicals	VA-044
Rosa26-nLacZ [FVB.Cg-Gt(ROSA)26Sortm1 (CAG-lacZ,-EGFP)Glh/J]	Jackson Laboratories	Jax Stock No:012429
Sodium Azide	Sigma Aldrich	S2002-5G
Sodium Chloride solution	Hospira, Inc.	NDC 0409-4888-10
Tamoxifen	Sigma Aldrich	T5648
Tamoxifen food	Envigo	TD.130860
Tween-20	Thermo Fisher Scientific	BP337-500
Quadrol, N,N,N′,N′-Tetrakis(2-Hydroxypropyl)ethylenediamine, decolorizing agent	Millipore Sigma	122262-1L
X-Clarity electrophoretic clearing chamber	Logos Biosystems	C30001
X-Clarity electrophoretic clearing solution	Logos Biosystems	C13001
X-Clarity electrophoresis tissue basket	Logos Biosystems	C12001
X-Clarity electrophoresis tissue basket holder	Logos Biosystems	C12002